Literature DB >> 21729684

Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.

Mehmet Asim Bilen1, Rosale General, Shi-Ming Tu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21729684      PMCID： PMC3205279          DOI： 10.1016/j.clgc.2011.04.003

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  25 in total

Review 1.  Glucocorticoid receptor signaling and prostate cancer.

Authors:  E Kassi; P Moutsatsou
Journal:  Cancer Lett       Date:  2011-03-01       Impact factor: 8.679

2.  Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.

Authors:  C N Robertson; K M Roberson; G M Padilla; E T O'Brien; J M Cook; C S Kim; R L Fine
Journal:  J Natl Cancer Inst       Date:  1996-07-03       Impact factor: 13.506

Review 3.  Carcinoma of the prostate.

Authors:  R F Gittes
Journal:  N Engl J Med       Date:  1991-01-24       Impact factor: 91.245

4.  Chronic intravascular coagulation. Clinical spectrum and diagnostic criteria, with special emphasis on metabolism, distribution and localization of I 131 -fibrinogen.

Authors:  P W Straub
Journal:  Acta Med Scand Suppl       Date:  1971

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series.

Authors:  Andrew Lawton; Gary Sudakoff; Lisa C Dezelan; Nancy Davis
Journal:  J Palliat Med       Date:  2010-09       Impact factor: 2.947

7.  Disseminated intravascular coagulation in carcinoma of prostate: role of estrogen therapy.

Authors:  S L Goldenberg; H N Fenster; Z Perler; M G McLoughlin
Journal:  Urology       Date:  1983-08       Impact factor: 2.649

8.  Prostate cancer detection is also relevant in low prostate specific antigen ranges.

Authors:  Marcos Lujan; Alvaro Paez; Elena Miravalles; Inmaculada Fernandez; Luis Llanes; Antonio Berenguer
Journal:  Eur Urol       Date:  2004-02       Impact factor: 20.096

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study.

Authors:  M Bonet; A Merglen; G Fioretta; E Rapiti; I Neyroud-Caspar; R Zanetti; R Miralbell; C Bouchardy
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.